Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6486523 | Biotechnology Advances | 2018 | 70 Pages |
Abstract
The diversity of natural compounds is essential for their mechanism of action. The source, structures and structure activity relationship of natural compounds contributed to the development of new classes of chemotherapy agents for over 40â¯years. The availability of combinatorial chemistry and high-throughput screening has fueled the challenge to identify novel compounds that mimic nature's chemistry and to predict their macromolecular targets. Combining conventional and targeted therapies helped to successfully overcome drug resistance and prolong disease-free survival. Here, we aim to provide an overview of preclinical investigated natural compounds alone and in combination to further improve personalization of cancer treatment.
Keywords
CSCE2FDiallyl tetrasulfideDADSCRPCeIF4Ediallyl trisulfideDATSDnmtBcl-xLAP-1CMLCGSBcl-2COX-2EGCGAMLEGFERBB2CDCeukaryotic translation initiation factor 4EDNA methyltransferaseDIMBoswellic acidepigallocatechin gallateNatural compoundsEMTTargeted therapyCastration-resistant prostate cancerCancer stem cellsCyclooxygenase-2ChemotherapyElongation factor 2Epithelial growth factorB-cell lymphoma-2acute myeloid leukemiaChronic myeloid leukemiaactivator protein-1Precision medicineCell division cycleEpithelial-mesenchymal transitionCardiac glycosidesEstrogen receptor
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Aloran Mazumder, Claudia Cerella, Marc Diederich,